New anemia pill could boost energy in dialysis patients
NCT ID NCT07537816
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding a pill called vadadustat to standard anemia treatment helps people on dialysis feel better and have higher hemoglobin levels. Forty adults on peritoneal dialysis will receive either vadadustat plus their usual shot or just the shot alone for 8 weeks, then switch. Researchers will track blood counts, quality of life, and inflammation to see if the combination works better.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Vadadustat (a pill for anemia)
- What this could lead to
- If it works, this could point toward a better way to manage anemia in dialysis patients, potentially improving their energy and quality of life.
- What could go wrong
- This is a small, early-phase study with only 40 participants, so results may not apply to everyone. The treatment is added to existing therapy, so any benefit may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 years or older * Receiving maintenance peritoneal dialysis * Followed at the outpatient clinics of MacKay Memorial Hospital * Receiving background darbepoetin alfa therapy * Able and willing to provide informed consent Exclusion Criteria: * Blood pressure \>170/80 mmHg on three separate occasions * Recent cardiovascular events within the past 3 months, including coronary artery disease, myocardial ischemia, cerebrovascular disease, or peripheral artery disease * Gastrointestinal bleeding within the past 3 months * Active malignancy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Renal anemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.